Stockscreener 앱 받기
11.65
0.52%
0.06
시간 외 거래:
11.55
-0.10
-0.86%
전일 마감가:
$11.59
열려 있는:
$11.65
하루 거래량:
5.49M
Relative Volume:
0.60
시가총액:
$13.42B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-3.6751
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
+6.59%
1개월 성능:
+5.81%
6개월 성능:
+28.16%
1년 성능:
-9.13%
1일 변동 폭
$11.50
$11.72
1주일 범위
$10.94
$11.72
52주 변동 폭
$6.85
$12.84
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
VTRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
11.65 | 13.35B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Risk Analysis: How Viatris Inc VIA stock behaves in tightening cyclesJuly 2025 Snapshot & Verified Swing Trading Watchlist - moha.gov.vn
Discipline and Rules-Based Execution in VTRS Response - news.stocktradersdaily.com
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
How Viatris Inc stock reacts to global recession fearsJuly 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn
Viatris to Sell Entire Equity Stake in Biocon Biologics for $815 Million - Voice Of HealthCare
Barclays Initiates Coverage of Viatris (VTRS) with Overweight Recommendation - Nasdaq
Barclays Initiates Viatris at Overweight With $15 Price Target - marketscreener.com
Viatris to sell equity stake in Biocon Biologics to Biocon for $815M - MSN
Generic Drugs Market to Reach US$ 942.69 Billion by 2033 at 7.1% - openPR.com
CAM, Khaitan act on Biocon Limited acquiring stake in Biocon Biologics from Serum, Viatris - Bar and Bench
Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛
Viatris Sells Biocon Biologics Stake for $815 Million - TipRanks
Viatris Inc Announces Agreement to Monetize Biocon Biologics Stake - TradingView — Track All Markets
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal - MSN
Viatris to Sell its Equity Stake in Biocon Biologics for $815 Million - marketscreener.com
Viatris signs agreements with Biocon on $815m stake sale - Yahoo Finance
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal (VTRS:NASDAQ) - Seeking Alpha
Viatris sells Biocon Biologics stake for $815 million - MSN
Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln - Nasdaq
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - PR Newswire
Biocon To Absorb Biocon Biologics, Pursue Rs 4,500 Cr QIP To Fund Viatris Payout - BW Businessworld
Biocon to absorb biologics unit, eyes Rs 4,500 cr fund raise to buy Viatris’s residual stake - Moneycontrol
Biocon integrates Biocon Biologics; to raise ₹4,500 crore via QIP to fund Viatris payout - BusinessLine
Viatris shareholders elect directors and approve proposals at annual meeting By Investing.com - Investing.com Nigeria
Viatris Holds Annual Shareholder Meeting on December 5 - TipRanks
Viatris shareholders elect directors and approve proposals at annual meeting - Investing.com India
Mark Cuban Takes Aim at FDA Fees - GuruFocus
Why Viatris Inc. (VIA) stock trades below fair valueJuly 2025 Pullbacks & Weekly Top Gainers Alerts - Newser
Mark Cuban calls for end to generic drug application fees to boost domestic manufacturing - Seeking Alpha
Can Viatris Inc. (VIA) stock survive global slowdownWall Street Watch & Free Daily Entry Point Trade Alerts - Newser
Can Viatris Inc. (VIA) stock surprise markets with earningsTrade Volume Summary & Low Drawdown Momentum Ideas - Newser
What is the fair value estimate for Viatris Inc. (VIA) stock in 2025Weekly Stock Analysis & AI Based Buy/Sell Signal Reports - Newser
Why Viatris Inc. (VIA) stock is a must watch tickerJuly 2025 Patterns & Risk Controlled Daily Plans - Newser
Is Viatris Inc. (VIA) stock a good hedge against inflationMarket Growth Summary & Stock Portfolio Risk Management - Newser
How Viatris Inc. stock benefits from global expansion2025 Top Gainers & High Conviction Investment Ideas - Newser
Will Viatris Inc. (VIA) stock extend growth storyMarket Risk Summary & Risk Managed Investment Strategies - Newser
How Viatris Inc. (VIA) stock compares with market leadersWeekly Stock Report & Step-by-Step Swing Trade Plans - Newser
Viatris Inc.: Revenue and Earnings Analysts Forecasts Revisions | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Target Price Consensus and Analysts Recommendations | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Financial Data Forecasts Estimates and Expectations | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Dividend historical data and projections - marketscreener.com
What market sentiment indicators show for Viatris Inc. (VIA) stockJuly 2025 Big Picture & Technical Buy Zone Confirmations - Newser
Behavioral Patterns of VTRS and Institutional Flows - news.stocktradersdaily.com
Levi & Korsinsky Notifies Viatris Inc. (VTRS) Shareholders of Class Action Lawsuit and June 3, 2025 Deadline - The National Law Review
VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
How Viatris Inc. (VIA) stock trades after earningsMarket Rally & Risk Controlled Stock Pick Alerts - moha.gov.vn
Non-operating income (total) of Viatris, Inc. – SIX:VTRS - TradingView
Viatris Inc. (VIA.DE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Shareholders That Lost Money on Viatris Inc. (VTRS) Should Contac - The National Law Review
These 10 S&P 500 Stocks Are Dirt Cheap This Black Friday - Benzinga
Merz Loses Bid To Block Viatris In Unified Patent Court - Law360
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
0.09%
자본화:
|
볼륨(24시간):